|
[1]BERNSTEIN CN,BLANCHARD JF,RAWSTHORNE P,et al.The prevalence of extraintestinal diseases in inflammatory bowel disease:Apopulation-based study[J].Am J Gastroenterol,2001,96(4):1116-1122．
|
|
[2]GARBER A,REGUEIRO M.Extraintestinal manifestations of inflammatory bowel disease:Epidemiology,etiopathogenesis,and management[J].Curr Gastroenterol Rep,2019,21(7):31．
|
|
[3]FENG Y,LIU YL.Progress of the extraintestinal manifestations of inflammatory bowel disease[J].Chin J Gastroenterol Hepatol,2015,24(6):631-640.(in Chinese)冯云，刘玉兰．炎症性肠病的肠外表现的研究进展[J]．胃肠病学和肝病学杂志，2015,24(6):631-640．
|
|
[4]VAVRICKA SR,BRUN L,BALLABENI P,et al.Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort[J].Am J Gastroenterol,2011,106(1):110-119．
|
|
[5]VAVRICKA SR,ROGLER G,GANTENBEIN C,et al.Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the Swiss inflammatory bowel disease cohort[J].Inflamm Bowel Dis,2015,21(8):1794-1800．
|
|
[6]KARLSEN TH.Primary sclerosing cholangitis:50 years of a gut-liver relationship and still no love?[J].Gut,2016,65(10):1579-1581．
|
|
[7]SRENSEN J，NIELSEN OH,ANDERSSON M,et al.Inflammatory bowel disease with primary sclerosing cholangitis:A Danish population-based cohort study 1977-2011[J].Liver Int,2018,38(3):532-541．
|
|
[8]GUERRA I,BUJANDA L,CASTRO J,et al.Clinical characteristics,associated malignancies and management of primary sclerosing cholangitis in inflammatory bowel disease patients:A multicentre retrospective cohort study[J].J Crohns Colitis,2019,13(12):1492-1500．
|
|
[9]KARLSEN TH,FOLSERAAS T,THORBURN D,et al.Primary sclerosing cholangitis-a comprehensive review[J].J Hepatol,2017,67(6):1298-1323．
|
|
[10]de VRIES AB,JANSE M,BLOKZIJL H,et al.Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis[J].World JGastroenterol,2015,21(6):1956-1971．
|
|
[11]MERTZ A,NGUYEN NA,KATSANOS KH,et al.Primary sclerosing cholangitis and inflammatory bowel disease comorbidity:An update of the evidence[J].Ann Gastroenterol,2019,32(2):124-133．
|
|
[12]HARBORD M,ANNESE V,VAVRICKA SR,et al.The first european evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease[J].J Crohns Colitis,2016,10(3):239-254．
|
|
[13]RABINOVITZ M,GAVALER JS,SCHADE RR,et al.Does primary sclerosing cholangitis occurring in association with inflammatory bowel disease differ from that occurring in the absence of inflammatory bowel disease?A study of sixty-six subjects[J].Hepatology,1990,11(1):7-11．
|
|
[14]YANAI H,MATALON S,ROSENBLATT A,et al.Prognosis of primary sclerosing cholangitis in israel is independent of coexisting inflammatory bowel disease[J].J Crohns Colitis,2015,9(2):177-184．
|
|
[15]LUDWIG J,BARHAM SS,LARUSSO NF,et al.Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis[J].Hepatology,1981,1(6):632-640．
|
|
[16]CHAPMAN MH,THORBURN D,HIRSCHFIELD GM,et al.British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis[J].Gut,2019,68(8):1356-1378．
|
|
[17]CHAZOUILLRES O.24-Norursodeoxycholic acid in patients with primary sclerosing cholangitis:A new“urso saga”on the horizon?[J].J Hepatol,2017,67(3):446-447．
|
|
[18]Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association;Chinese Society of Infectious Diseases,Chinese Medical Association.Consensus on the diagnosis and management of primary sclerosing cholangitis(2015)[J].J Clin Hepatol,2016,32(1):23-31.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会．原发性硬化性胆管炎诊断和治疗专家共识(2015)[J]．临床肝胆病杂志，2016,32(1):23-31．
|
|
[19]SHAH A,CRAWFORD D,BURGER D,et al.Effects of antibiotic therapy in primary sclerosing cholangitis with and without inflammatory bowel disease:A systematic review and meta-analysis[J].Semin Liver Dis,2019,39(4):432-441．
|
|
[20]JESS T,RUNGOE C,PEYRIN-BIROULET L.Risk of colorectal cancer in patients with ulcerative colitis:A meta-analysis of population-based cohort studies[J].Clin Gastroenterol Hepatol,2012,10(6):639-645．
|
|
[21]ZHENG HH,JIANG XL.Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease:A meta-analysis of 16 observational studies[J].Eur J Gastroenterol Hepatol,2016,28(4):383-390．
|
|
[22] Inflammatory Bowel Disease Group,Chinese Society of Gastroenterology,Chinese Medical Association.Chinese consensus on diagnosis and treatment in inflammatory bowel disease(2018,Beijing)[J].Chin JDig,2018,38(5):292-311.(in Chinese)中华医学会消化病学分会炎症性肠病学组．炎症性肠病诊断与治疗的共识意见(2018年，北京)[J]．中华消化杂志，2018,38(5):292-311．
|
|
[23]AABAKKEN L,KARLSEN TH,ALBERT J,et al.Role of endoscopy in primary sclerosing cholangitis:European Society of Gastrointestinal Endoscopy(ESGE)and European Association for the Study of the Liver(EASL)clinical guideline[J].Endoscopy,2017,49(6):588-608．
|
|
[24]HUAI JP,DING J,YE XH,et al.Inflammatory bowel disease and risk of cholangiocarcinoma:Evidence from a meta-analysis of population-based studies[J].Asian Pac J Cancer Prev,2014,15(8):3477-3482．
|
|
[25]ANANTHAKRISHNAN AN,CAGAN A,GAINER VS,et al.Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease[J].J Crohns Colitis,2014,8(9):956-963．
|
|
[26]BOWLUS CL,LIM JK,LINDOR KD.AGA clinical practice update on surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis:Expert review[J].Clin Gastroenterol Hepatol,2019,17(12):2416-2422．
|
|
[27]CHARATCHAROENWITTHAYA P,ANGULO P,ENDERS FB,et al.Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis[J].Hepatology,2008,47(1):133-142．
|
|
[28]BJRNSSON E,OLSSON R,BERGQUIST A,et al.The natural history of small-duct primary sclerosing cholangitis[J].Gastroenterology,2008,134(4):975-980．
|
|
[29] CHEN CH,LIN CL,KAO CH.Association between inflammatory bowel disease and cholelithiasis:A nationwide population-based cohort study[J].Int J Environ Res Public Health,2018,15(3):513．
|
|
[30]GIZARD E,FORD AC,BRONOWICKI JP,et al.Systematic review:The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease[J].Aliment Pharmacol Ther,2014,40(1):3-15．
|
|
[31]Editorial Board of Chinese Journal of Digestion,Cooperation Group of Hepatobiliary Diseases of Chinese Society of Gastroenterology.Consensus on diagnosis and treatment of chronic cholecystitis and gallstones in China(2018)[J].J Clin Hepatol,2019,35(6):1231-1236.(in Chinese)中华消化杂志编辑委员会，中华医学会消化病学分会肝胆疾病协作组．中国慢性胆囊炎、胆囊结石内科诊疗共识意见(2018年)[J]．临床肝胆病杂志，2019,35(6):1231-1236．
|
|
[32]DASTIS SN,LATINNE D,SEMPOUX C,et al.Ulcerative colitis associated with Ig G4 cholangitis:Similar features in two HLA identical siblings[J].J Hepatol,2009,51(3):601-605．
|
|
[33]DESHPANDE V,ZEN Y,CHAN JK,et al.Consensus statement on the pathology of Ig G4-related disease[J].Mod Pathol,2012,25(9):1181-1192．
|
|
[34]POLYCHRONOPOULOU E,LYGOURA V,GATSELIS NK,et al.Increased cholestatic enzymes in two patients with long-term history of ulcerative colitis:Consider primary biliary cholangitis not always primary sclerosing cholangitis[J].BMJ Case Rep,2017,2017:bcr2017220824．
|
|
[35]XIAO WB,LIU YL.Primary biliary cirrhosis and ulcerative colitis:Acase report and review of literature[J].World J Gastroenterol,2003,9(4):878-880．
|
|
[36]Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association;Chinese Society of Infectious Diseases,Chinese Medical Association.Consensus on the diagnosis and management of primary biliary cirrhosis(cholangitis)(2015)[J].J Clin Hepatol,2015,31(12):1980-1988.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会．原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015)[J]．临床肝胆病杂志，2015,31(12):1980-1988.
|
DownLoad: